Tris Pharma, Inc. v. Actavis Laboratories FL, Inc., No. 21-1495 (Fed. Cir. July 7, 2022)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Appellant Tris Pharma, Inc. (Tris) owns U.S. Patent Nos. 8,465,765 (’765 patent), 8,563,033 (’033 patent), and 8,778,390 (’390 patent). Tris asserted claims of all three patents against Appellee Actavis Laboratories FL, Inc. (Ac- tavis) in the United States District Court for the District of Delaware. Following a five -day bench trial, the district court held that all asserted claims would have been obvious under 35 U.S.C. § 103. Tris Pharma, Inc. v. Actavis Lab’ys FL, Inc., 276 F. Supp. 3d 226, 249 (D. Del. 2017).